Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-9805 in Advanced KRAS G12D-Mutant Solid Tumors
NCT06040541Phase 1Recruiting
- Sponsor
- Revolution Medicines
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zoldonrasib in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more (2 arms), sponsored by Revolution Medicines. Primary endpoints: Adverse Events at 3 years and Dose Limiting Toxicities at 21 days. Started Sep 2023; status: recruiting.
02
Drugs
zoldonrasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06040541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040541.